Activity

Adult Fibrosarcoma (FS) is very rare and it constitutes approximately 1% of adult sarcomas. It is a malignant or intermediate (rarely metastasizing) tumor, composed of fibroblasts with variable collagen production. Fibrosarcomas usually involve the deep tissues of the extremities, trunk, head and neck. Adult FS usually appears in the fourth to sixth decades of life with a male predominance.

A 62 years male patient presented with a large swelling over anterior abdominal wall since 20 years. Physical examination revealed a 15 × 15 cm large lobulated swelling situated over right hypochondrium and extending to epigastrium and right lumbar region. A wide local excision of tumour was done till the posterior rectus sheath. As the skin was involved the tumour was excised along with the skin. A large defect of around 20 × 20 cm was created in anterior abdominal wall. Mesh was placed over the defect and defect was closed by rhomboid flap reconstruction.

The World Health Organization (2002) defined fibrosarcoma as a malignant tumor, composed of fibroblasts with variable collagen and, in classical cases, it has a herring bone pattern on light microscopy. Fibrosarcomas typically present as a non-specific soft tissue mass, sometime in a previously irradiated field or rarely in association with implanted foreign material. Fibrosarcomas metastasize to lungs and bone, especially the axial skeleton, and rarely to lymph nodes.

Although rare, fibrosarcoma should also be kept as a differential diagnosis in a case of anterior abdominal wall lumps.

Although rare, fibrosarcoma should also be kept as a differential diagnosis in a case of anterior abdominal wall lumps.Sucralose, one of the popular non-caloric artificial sweeteners, has been known to influence the enzymatic conversion of sucrose to glucose and fructose by invertase. In continuing the use of real-time NMR experiments and reaction progress curve analysis to measure enzyme kinetics, here we investigate the role of sucralose as an inhibitor. 4SC-202 inhibitor NMR based kinetic experiments were performed as a function of the substrate concentration for a range of sucralose concentrations, and the results were analyzed by fitting the progress curve to the Lambert-W function. The Michaelis-Menten parameters were then used to estimate the inhibitory constant of sucralose. To estimate the extent of sucralose inhibition on the enzymatic production of glucose, control experiments were performed with lactose as the inhibitor under similar experimental conditions. The results show that sucralose is a much more potent inhibitor than lactose, inhibiting the enzymatic conversion at least seven times more.

A large proportion of patients with inflammatory bowel disease (IBD) receive immunosuppressive medication, may be at higher risk of complications if they contract SARS-CoV-2 virus, and therefore report high levels of COVID-19-related distress. This trial will evaluate a brief, evidence-based, online, group-based expressive writing intervention to reduce COVID-19-related distress in people living with IBD at the time of pandemic.

A parallel double-blind randomised controlled trial will be conducted. Overall, up to 154 adult participants with IBD and mild-moderate distress will be recruited via patient organisations. Participants will be allocated to the expressive writing intervention or an active control group. All participants will complete questionnaires including measures of distress, quality of life, resilience, self-efficacy, social support and disease activity before and after the intervention (1week) and at 3months post-intervention. The expressive writing group will participate in the evidenced-based 4-day writing program adapted from Pennebaker and Beall, 1986. The active control group will write about untherapeutic topics provided by researchers. Statistical analysis will be carried out on an intention-to-treat basis and will involve linear mixed effects models.

If successful, this simple intervention may bring personal and societal benefits, particularly because it is low cost, can be easily implemented online, ensuring social distancing, and be made widely available, during future disasters and to help with trauma-related distress in IBD.

The trial has been prospectively registered in the Australian New Zealand Trial Registry – ACTRN12620000448943p.

The trial has been prospectively registered in the Australian New Zealand Trial Registry – ACTRN12620000448943p.The present report documents a patient harboring an alpha-synuclein p.A53T variant from a family presenting with autosomal dominant inheritance, including four patients clinically diagnosed with Parkinson’s disease (PD) and two with dementia. The alpha-synuclein p.A53T variant is linked to young- or middle-aged onset parkinsonism and cognitive decline. Our patient had a different haplotype from that of a patient with a p.A53T variant from an Italian family. The proband presented at 42 years of age with progressive parkinsonism and good response to levodopa in the early stages of the disease. At 46 years of age, he developed delusions and cognitive decline. Brain magnetic resonance imaging showed bilateral atrophic changes in the hippocampus and temporal lobes. He died of pneumonia at the age of 52 years. Neuropathological examination revealed severe neuronal loss in the substantia nigra, locus coeruleus, and dorsal nucleus of the vagus nerve, as well as widespread Lewy pathology including Lewy bodies and neurites, corresponding to Braak stage 6, and diffuse neocortical-type PD. There was mild appearance of tau pathology and glial cytoplasmic inclusion, in the absence of TDP-43 pathology. Alpha-synuclein p.A53T characteristically cause the Lewy body pathology and the symptoms, that resembled those of the reported patients with p.A53T.Preeclampsia (PE) and vascular dysfunction are major causes of maternal and neonatal morbidity and mortality. Although extensively studied, the complete understanding of the pathophysiology behind PE remains unclear. Current reports indicate that exosomes are essential mediators in PE-related cardiovascular disease (CVDs). Exosomes are synthesized from multivesicular bodies (MVB) and contain functionally active microRNAs miRNAs). These miRNAs have been shown to mediate physiological and pathological functions through autocrine, paracrine, and endocrine signaling mechanisms. The role of miRNAs in pregnant women with PE has been studied extensively. However, little is known about the effect of exosomal miRNAs (exomiR) in PE. This paper will review and discuss the existing evidence for exomiR function in PE and highlight the need for future studies to explore the role that exomiR signatures have in cardiovascular dysfunction associated with PE.